
NanoTalks
- Miguel Ángel Esteve
- 26/05/2026
Polymers for Drug Conjugation: From PEGylation to Next-Generation Polymer Therapeutics
Explore how polymer selection defines the pharmacokinetics, safety profile, and translational potential of polymer–drug conjugates.
This article examines how key parameters such as polymer backbone chemistry, molecular weight, architecture, degradability, and functionalization capacity directly influence circulation time, biodistribution, drug loading, and release behavior. It also highlights the strengths and limitations of established and emerging polymers, including PEG, polysarcosine (PSar), PGA, PLGA, HPMA, and POx, and shows how next-generation strategies like PSarylation and precision-engineered copolymers are enabling more programmable, biodegradable, and clinically adaptable therapeutic systems.
Recent Articles
- Filter by:
- All
- LNP
- Polymers
- Analytics
- Regulatory
- Miguel Ángel Esteve
- May 26, 2026
- Miguel Ángel Esteve
- April 28, 2026
- Miguel Ángel Esteve
- April 2, 2026
- Miguel Ángel Esteve
- February 26, 2026
- Miguel Ángel Esteve
- January 29, 2026
- Miguel Ángel Esteve
- December 18, 2025
- Miguel Ángel Esteve
- November 13, 2025
- Miguel Ángel Esteve
- October 15, 2025
- Miguel Ángel Esteve
- September 11, 2025
- Miguel Ángel Esteve
- July 30, 2025
Sign Up for NanoTalks
Subscribe to NanoTalks, the magazine of Curapath. Stay up to date on the latest developments, trends and news in the world of non-viral vectors, plus discover the latest advances in nanobiotechnology.
